INSERM U735, Institut Curie Hôpital René Huguenin, St-Cloud, France.
Mol Cancer. 2011 Feb 27;10:23. doi: 10.1186/1476-4598-10-23.
Aneuploidy and chromosomal instability (CIN) are common abnormalities in human cancer. Alterations of the mitotic spindle checkpoint are likely to contribute to these phenotypes, but little is known about somatic alterations of mitotic spindle checkpoint genes in breast cancer.
To obtain further insight into the molecular mechanisms underlying aneuploidy in breast cancer, we used real-time quantitative RT-PCR to quantify the mRNA expression of 76 selected mitotic spindle checkpoint genes in a large panel of breast tumor samples.
The expression of 49 (64.5%) of the 76 genes was significantly dysregulated in breast tumors compared to normal breast tissues: 40 genes were upregulated and 9 were downregulated. Most of these changes in gene expression during malignant transformation were observed in epithelial cells.Alterations of nine of these genes, and particularly NDC80, were also detected in benign breast tumors, indicating that they may be involved in pre-neoplastic processes.We also identified a two-gene expression signature (PLK1 + AURKA) which discriminated between DNA aneuploid and DNA diploid breast tumor samples. Interestingly, some DNA tetraploid tumor samples failed to cluster with DNA aneuploid breast tumors.
This study confirms the importance of previously characterized genes and identifies novel candidate genes that could be activated for aneuploidy to occur. Further functional analyses are required to clearly confirm the role of these new identified genes in the molecular mechanisms involved in breast cancer aneuploidy. The novel genes identified here, and/or the two-gene expression signature, might serve as diagnostic or prognostic markers and form the basis for novel therapeutic strategies.
非整倍体和染色体不稳定性(CIN)是人类癌症中的常见异常。有丝分裂纺锤体检查点的改变可能导致这些表型,但关于乳腺癌中纺锤体检查点基因的体细胞改变知之甚少。
为了更深入地了解乳腺癌中非整倍体的分子机制,我们使用实时定量 RT-PCR 定量分析了大量乳腺癌肿瘤样本中 76 个选定的纺锤体检查点基因的 mRNA 表达。
与正常乳腺组织相比,76 个基因中有 49 个(64.5%)的表达明显失调:40 个基因上调,9 个基因下调。这些基因在恶性转化过程中的大多数表达变化都发生在上皮细胞中。这些基因中的九个基因(特别是 NDC80)的改变也在良性乳腺肿瘤中检测到,表明它们可能参与了前肿瘤过程。我们还确定了一个由两个基因(PLK1+AURKA)组成的表达特征,可以区分 DNA 非整倍体和 DNA 二倍体乳腺癌样本。有趣的是,一些 DNA 四倍体肿瘤样本未能与 DNA 非整倍体乳腺癌肿瘤聚类。
本研究证实了以前鉴定的基因的重要性,并确定了新的候选基因,这些基因可能被激活以发生非整倍体。需要进一步的功能分析来明确确认这些新鉴定的基因在乳腺癌非整倍体涉及的分子机制中的作用。这里鉴定的新基因,和/或两个基因表达特征,可能作为诊断或预后标志物,并为新的治疗策略提供基础。